Ranbaxy Laboratories and its new owner Japan’s Daiichi Sankyo, which now holds 63.92% of Ranbaxy’s equity share capital, reconstituted a new 10-member panel. Besides persisting in with his existing duties as CEO & MD, Malvinder Mohan Singh has been nominated as the chairman of Ranbaxy.

 

From the company’s earlier 15 member panel, the company retained only three members including former owner Malvinder Singh, COO Atul Sobti and Religare CEO & MD Sunil Godhwani. Atul Sobti would continue in his role as the Chief Operating Officer.

 

Daiichi Sankyo’s president and CEO Takashi Shoda, and Senior Executive Officer Tsutomu Une, have also been nominated in the board as directors. The newly announced board reflects the changed ownership structure at Ranbaxy, following Daiichi Sankyo’s strategic investment during the last month (Nov 2008).

 

Malvinder Singh has also been announced as a member of senior global management team of Daiichi Sankyo. The other directors include Anthony Wild, Partner, BOWS Pharmaceuticals AG; Rajesh Shah, Co-chairman and MD, Mukand Ltd; Sunil Godhwani, CEO and MD, Religare Enterprise Ltd; Akhiro Watanabe, Representative Director, GCA Savvian Group; and Balinder Singh Dhillon, an advocate.